The advent of anti–vascular endothelial growth factor (anti-VEGF) therapy has represented a paradigm shift in the treatment of neovascular age-related macular degeneration (nAMD). However, anti-VEGF injections require frequent office visits for administration to maintain visual acuity gains, placing a considerable treatment burden on patients, caregivers, and the health care system. Achieving sustained efficacy with fewer injections has been a major focus of research into new therapeutic options for nAMD.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
De La Huerta I, Kim SJ, Sternberg P. Faricimab Combination Therapy for Sustained Efficacy in Neovascular Age-Related Macular Degeneration. JAMA Ophthalmol. Published online July 30, 2020. doi:10.1001/jamaophthalmol.2020.2723
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: